AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00469443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 150mg/m2 IV on day 1 every 2 weeks for 10 cycles
Study NCT00469443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil 400 mg/m2 infused over 10 min IV and 5-FU 600 mg/m2 infused over 22 hours IV, on Day 1 and 2 (De Grammont regimen), every 2 weeks for 10 cycles
Study NCT00469443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 200 mg/m2 infused over 2 hours IV, on day 1 and 2 every 2 weeks for 10 cycles
Study NCT00469443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 2000mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
Study NCT00469443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5mg/kg IV on day 1 every 2 weeks for 10 cycles
Study NCT00469443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 7,5mg/kg IV on day 1 every 3 weeks for 6 cycles
Study NCT00469443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 250mg/m2 IV on day 1 every 3 weeks for 6 cycles
Study NCT01299636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM060184
Description: PM060184 administered intravenously (i.v.) over 10 minutes at a starting dose of 4 mg/m2/day on three consecutive days q2w (on Days 1-3 and 15-17) every 28 days.
Study NCT04047342 — intervention group
Intervention type: BEHAVIORAL
Intervention: Welcome email
Description: Email
Study NCT04047342 — intervention group
Intervention type: BEHAVIORAL
Intervention: Loss frame
Description: Email
Study NCT00386035 — intervention group
Intervention type: DRUG
Intervention: Delayed ART
Description: Participants follow a drug conservation (DC) regimen in which ART is stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count is at least 350 cells/mm3, and then are followed by episodic ART based on CD4 cell count.
Study NCT00386035 — intervention group
Intervention type: DRUG
Intervention: Continuous ART
Description: Group 2 participants follow a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count.
Study NCT04369742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Description: HCQ 400mg (2 tab) by mouth BID (day 1), 200mg (1 tab) by mouth BID (days 2-5)
Study NCT04369742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Calcium citrate
Description: Calcium citrate 2 tablets (400mg) BID on day 1, 1 tablet (200mg) on days 2-5
Study NCT02012257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AMSA nerve block injectio
Description: Sites of injection
Study NCT01861587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 20 minutes of either real or sham stimulation
Study NCT00768040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: 300 mg once daily
Study NCT00768040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo once daily
Study NCT04041401 — intervention group
Intervention type: OTHER
Intervention: PICU storybook
Description: Narrative and developmentally appropriate intervention
Study NCT00955682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One intramuscular dose (Booster)
Study NCT00955682 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec™
Description: One intramuscular dose (Booster)
Study NCT02349841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: To administer 2g daily 8 hourly for 14 days
Study NCT02349841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faropenem
Description: To adminster 600mg 8 hourly daily for 14 days
Study NCT02349841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanic acid
Description: To administer 625mg 8 hourly daily for 14 days together with the faropenem and meropenem
Study NCT02349841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifafour e275
Description: To be taken as per the National TB treatment programme for 14 days
Study NCT01388205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based Outdoor program
Description: 2 to 3 hour outdoor activities organized in conjunction with National Parks, Singapore
Study NCT02468076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (StarMed)
Description: Radiofrequency ablation into bile duct
Study NCT02533011 — intervention group
Intervention type: OTHER
Intervention: HBP lab test
Description: Plasma level of Heparin Binding Protein will be evaluated on extra blood specimens already collected as part of standard of care.
Study NCT01258738 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: In Period 1, subjects will receive in a prefilled syringe with 1.0 ml (test article Etanercept (SC) once weekly . Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
Study NCT01258738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Background NSAID
Description: Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by their attending physician. The name and dose of this NSAID is the decision of the attending physician.
Study NCT01258738 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: In Period 1 will receive a prefilled syringe of Placebo for Etanercept Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
Study NCT01258738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Background NSAID
Description: Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by attending physician (dose drug selection as tolerated and agreed upon by the attending Physician).
Study NCT03637504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MedActionPlan®
Description: web-based, mobile medication management application \[MedActionPlan® (MAP)\]
Study NCT03637504 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MedActionPlan®
Description: web-based, mobile medication management application \[MedActionPlan® (MAP)\]
Study NCT03815201 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 2
Description: leucine-enriched protein supplementation during the first 1/2 hour post-training
Study NCT03603691 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fatigue Scale for Motor and Cognitive Functions
Description: Measures cognitive and motor fatigue for people with MS
Study NCT03603691 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: numeric rating scale Fatigue
Description: visual analog scale that uses a scalar numbering system to objectify a patient's fatigue (0 = no fatigue; 10 = most extreme fatigue)
Study NCT01906905 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Study NCT04927507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet plus nursing home rehabilitation
Description: The observation group was given the Internet plus nursing home rehabilitation mode.~Relying on mobile app and wechat public service platform, patients can get online guidance of rehabilitation training video through app and wechat, and get professional rehabilitation guidance at any time.
Study NCT00003056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Study NCT00003056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine and methotrexate
Study NCT01144533 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline injection into the glenohumeral joint
Description: * Total volume of injection drugs: 8ml~* isotonic saline 4ml + telebrix(contrast media) 4ml~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection.
Study NCT01144533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: steroid injection into the glenohumeral joint
Description: * Total volume of injection drugs: 8ml~* triamcinolone(40mg)1ml + isotonic saline 3ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection.
Study NCT01144533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sodium hyaluronate injection into the glenohumeral joint
Description: * Total volume of injection drugs: 8ml~* sodium hyaluronate 2ml + isotonic saline 2ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection.
Study NCT01144533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: steroid and hyaluronate injection into the glenohumeral joint
Description: * Total volume of injection drugs: 8ml~* triamcinolone(40mg)1ml + sodium hyaluronate 2ml + isotonic saline 1ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection.
Study NCT03391700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium(deep)
Description: In the group with deep relaxation during surgery, rocuronium is given by continuous infusion (0.6 mg/kg/h).
Study NCT03391700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium(moderate)
Description: In the group with deep relaxation during surgery, rocuronium is given by bolus dose(0.15mg/kg) induced a train of four count of 1-2.
Study NCT03129009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total intravenous anesthesia group
Description: Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion
Study NCT03129009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced anesthesia group
Description: Balanced anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with cisatracurium and remifentanil target controlled infusion and sevoflurane inhalation
Study NCT01420198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Increased physical activity and improved food habits
Study NCT01633359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive statin
Description: the Intensive Atorvastatin protocol indicates that once 80mg Atorvastatin will be administrated before CAG, and then will be followed with 20mg Atorvastatin daily during the entire study period.
Study NCT01633359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine statin
Description: the Routine Atorvastatin protocol indicates that 20mg Atorvastatin daily during the entire study period.
Study NCT05281588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations
Description: All micro-osteoperforations were performed only one time in the experimental group on the same day of the installation of the upper incisors' retraction mechanics. Perforations were performed with an individualized surgical guide and a 1.6 mm diameter stainless steel surgical drill perpendicular to the alveolar bone, 3 mm deep on the buccal surface, and 5 mm, on the palate. The depth of the perforations was controlled and standardized by a cursor developed and patented by the research group. Two micro-osteoperforations were aligned vertically distally from each upper incisor. Due to the proximity of the roots in the cervical third, only the most apical perforation was performed between the two central incisors. The first perforation was performed 6 mm away from the gingival margin, and the second, 5 mm from the first, in the vertical direction.
Study NCT03028961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stanford Letter
Description: Receive and complete the Stanford Letter
Study NCT03028961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Undergo semi-structured, research staff-led interview
Study NCT03028961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Undergo semi-structured, research staff-led interview
Study NCT03028961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03028961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03028961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CA Advance Health Care Directive Form
Description: Receive and complete the CA Advance Health Care Directive Form
Study NCT02869230 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ROLL
Description: The ROLL technique (radioguided occult lesion localization) is characterized by the injection of a radiotracer in the center of the lesion
Study NCT02869230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wire-guided lesion localization
Description: wire-guided lesion localization, including better lesion centricity in relation to margins,decreased marking time, reduced surgery time, and better aesthetic outcomes
Study NCT02089425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-103-IP
Study NCT02089425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT01577875 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NBI with magnification
Description: After randomization of the subjects into two groups(1) NBI with magnification, 2) without magnification), one experienced endoscopist records its site, size, shape, and predicted histologic diagnosis on the every polyp observed and endoscopically resected. Two groups will be compared with each other.
Study NCT03841370 — intervention group
Intervention type: PROCEDURE
Intervention: endodontic treatment
Description: Color measurements of endodontically treated teeth (incisors, canines or premolar) will be collected regardless of technique, treatment time and sealer used.
Study NCT05684185 — intervention group
Intervention type: BIOLOGICAL
Intervention: Intramuscular (IM) rabies post-exposure prophylaxis
Description: one-site, 0.5 mL at Day 0, D3, D7 and D14
Study NCT05684185 — intervention group
Intervention type: BIOLOGICAL
Intervention: Intradermal (ID) rabies post-exposure prophylaxis
Description: two-site, 0.1 mL at Day 0, D3 and D7
Study NCT02625714 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Renexin®
Description: Cilostazol 100mg/ginko biloba leaf extract 80mg, Immediate release, bid
Study NCT02625714 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SID142
Description: Cilostazol 200mg/ginko biloba leaf extract 160mg, Controlled release, qd
Study NCT03249103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NYX-2925
Description: NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
Study NCT03249103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Matching placebo capsules.
Study NCT03784807 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: synovial calprotectin, confocal laser microscopy
Description: Calprotectin will be determined in synovial fluid of patients with septic and aseptic failure of their prosthesis. CLSM will be used to detect presence of microorganisms in synovial fluid. Susceptibility to antimicrobials of bacterial strains isolated from patients with prosthetic joint infections will be assessed using planktonic cells and biofilm associated bacteria
Study NCT03465930 — intervention group
Intervention type: PROCEDURE
Intervention: Supermicrosurgical lymphatico-venous anastomoses
Description: Supermicrosurgical lymphatico-venous anastomoses (sLVA) require an accurate visualization of the lymphatic vessels that are still functional. Lymphatic vessels are visualized with lymphography using a fluorescent dye, indocyanine green. Adjacent superficial veins mapping is obtained with Accuvein device.
Study NCT03286283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-Plasma
Description: Dermal resurfacing procedure with J-Plasma.
Study NCT03615066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet(s) administered orally every 7 days for 24 doses in fasted state
Study NCT03615066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet(s) administered orally every 7 days for 24 doses in fasted state
Study NCT03615066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selgantolimod
Description: Tablet(s) administered orally every 7 days for 24 doses in fasted state
Study NCT03615066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAF
Description: Tablet(s) administered orally once daily with food
Study NCT03615066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Tablet(s) administered orally once daily with food
Study NCT02359227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenderitide
Description: Cenderitide is a dual receptor natriuretic peptide.
Study NCT01577472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Clomiphencitrat
Description: 100mg of clomiphencitrate(Serophene®) are added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
Study NCT01577472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Clomiphencitrat
Description: 100mg of clomiphencitrate(Serophene®) are added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
Study NCT01577472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: High Dose Placebo
Description: Placebo is added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
Study NCT01577472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low dose Placebo
Description: Placebo is added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
Study NCT01973504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP4OX
Description: 4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
Study NCT01973504 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Crystalloid solution IV infusion drip to keep vein open
Study NCT02104947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarucizumab
Description: idarucizumab
Study NCT04130698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Tolerance
Description: The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with distress tolerance intervention to quit smoking and lose weight.
Study NCT04130698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transdermal nicotine patch
Description: Participants will use the patch for 8 weeks as outlined by the recommended usage for steps 1-3 going from 21mg for 4 weeks, 14mg for 1 week, and 7mg for 1 week.
Study NCT04130698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal nicotine patch
Description: Participants will use the patch for 8 weeks as outlined by the recommended usage for steps 1-3 going from 21mg for 4 weeks, 14mg for 1 week, and 7mg for 1 week.
Study NCT04130698 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Health Control
Description: The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with psychoeducation intervention to quit smoking and lose weight.
Study NCT02954666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radio-frequency ablation
Description: Patients will undergo a tailored 'radio-frequency ablation' of the ARGP with the Smart Touch™ catheter or with the nMARQ™ catheter. Radiofrequency applications will be interrupted if no significant P-P interval shortening is observed after 30 seconds or if P-P interval is ≤ 550 ms during ablation.~The ablation procedure is considered complete when one of the following conditions is fulfilled:~P-P interval \< 70% baseline procedural P-P interval after 5minute of waiting time; P-P interval \< 600 ms after 5 minute of waiting time; 5 radiofrequency applications > 30 seconds have been delivered with the nMARQ™ catheter or 10 applications with the Smart Touch catheter.
Study NCT02448290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel plus selumetinib
Description: Selumetinib will be administered orally 75mg twice a day continuously. Docetaxel will be administered as an IV infusion over 1 hour at 60 mg/m2 every 3 week of a 21 days schedule.